First medical cannabis safety compliance facility breaks ground in KY
Officials say State38 LLC, with a roughly $1 million investment, will employ around a dozen Kentuckians. The new safety compliance facility will be one of seven in the state dedicated to ensuring the safety and quality of medical cannabis products.
Owensboro Health commits $200K to community projects
'Team Kentucky is dedicated to ensuring every Kentuckian with a qualifying condition has safe access to quality medical cannabis,' said Gov. Andy Beshear. 'I'm excited to see this new industry take root here in Graves County, because I believe health care is a basic human right.'
Officials say on April 17, 2024, Gov. Beshear signed House Bill 829 into law, which moved up the timeline for medical cannabis licensing in Kentucky by six months. The Kentucky Office of Medical Cannabis began accepting applications from prospective businesses on July 1, 2024.
Officials with Gov. Beshear's office say last month, Team Kentucky broke ground on the first medical cannabis business in the state, Centaurus Farms KY LLC, a Tier II cultivator in Wayne County. A ribbon-cutting was also held for a Tier III cultivator facility in Clark County managed by Cresco Labs.
Two arrested after Hopkins County chase
'I'm proud to see the progress that's been made so far, and I look forward to the day when we say that all our safety compliance facilities, cultivators and dispensaries are open for business,' added Gov. Beshear.
Gov. Beshear says on March 31, 2023, Gov. Beshear signed Senate Bill 47 into law, legalizing medical cannabis for Kentuckians beginning January 1, 2025. To date, more than 15,000 Kentuckians have received a written certification, and over 10,000 have successfully applied for and received a medical cannabis card.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
2 days ago
- UPI
21 state AG's ask feds to ban 'designer Xanax' after Kentucky ban
1 of 2 | "This deadly drug has no place in our communities, and now we have the tools needed to get it off the streets and protect more lives," two-term Democratic Gov. Andy Beshear (pictured at the August 2024 DNC in Chicago, Ill.) said Monday. File Photo by Tannen Maury/UPI | License Photo Aug. 19 (UPI) -- Kentucky designated "bromazolam" as a Schedule 1 controlled substance as Gov. Andy Beshear also led a push to have it designated similarly at the federal level. Beshear announced the effort to ban the drug, also known as "designer Xanax" Monday after bromazolam was detected in at least 48 overdose deaths in Kentucky last year. "This deadly drug has no place in our communities, and now we have the tools needed to get it off the streets and protect more lives," the two-term Democratic governor said in a statement. The governor's signature immediately banned the drug from being sold in Kentucky and empowered law enforcement to act and arrest for sales or possession. It also provides further tools for authorities in Beshear's statewide crackdown. A 2021 report suggested that overdose deaths linked to illicit "designer" drugs had surged in the United States a staggering 520% between 2019 and 2020 during the COVID-19 pandemic, according to data from 32 states and the District of Columbia. On Monday, the rumored Democratic presidential candidate pointed to "important progress" in Kentucky's fight against addiction with three straight years of declines in overdose deaths. "And we're committed to ensuring that work continues," Beshear added. Beshear's executive action this week reportedly came following a request by the state's Republican Attorney General Russell Coleman. "We live in a moment when as little as one pill can kill -- and is killing -- our kids," Coleman said Monday in a joint statement with Beshear. "I'm glad we could work together to tackle this grave threat," he added on the bipartisan effort to rid the streets of the "designer" bromazolam. In 1985 the federal government enacted its ban on the so-called "designer drug" Ecstasy entirely due to the fact it was created by chemists and Ecstasy spin-offs were starting to hit the streets. Coleman and 20 other GOP state attorneys general are now calling on the federal government to follow state actions. "Despite its clear dangers, bromazolam remains unscheduled at the federal level, creating significant challenges for law enforcement and public health officials trying to respond to this emerging crisis," read a letter in part to DEA Administrator Terry Cole signed by Coleman and Alabama's Attorney General Steve Marshall, Tim Griffin in Arkansas, Florida's James Uthmeier, Georgia Attorney General Chris Carr, Indiana's Attorney General Todd Rokita and Brenna Bird from Iowa, Liz Murrill of Louisiana, Lynn Fitch of Mississippi, Montana's Austin Knudsen, Mike Hilgers of Nebraska, Drew Wrigley of North Dakota, Dave Yost of Ohio, Oklahoma's Gentner Drummond, Pennsylvania's new Attorney General Dave Sunday, Alan Wilson of South Carolina, Marty Jackley of South Dakota, Jonathan Skrmetti of Tennessee, Virgina's Jason Miyares, John 'JB' McCuskey of West Virginia and Ken Paxton of Texas. Coleman's letter pointed to how the originally synthesized but never approved for medical use bromazolam is now being illegally sold on the streets and in online platforms. The band of Republican state chief law enforcement officers argues that without its scheduling on a federal level, bromazolam will continue to "evade traditional regulatory and prosecutorial tools," which they added will hinder interdiction efforts and enable "continued distribution through illicit channels." "Virginia took proactive action by scheduling bromazolam," Virginia's Attorney General Jason Miyares said Monday. "Now, I'm encouraging federal action to ensure every state has the same tools to protect Americans," the Republican AG and first Latino elected to statewide office in Virginia posted on social media.
Yahoo
2 days ago
- Yahoo
BlueOval SK begins production one week out from pivotal union vote. Here's what that means
GLENDALE, Ky. ― BlueOval SK has begun production of electric vehicle batteries at its sprawling Hardin County plant, the company announced Aug. 19, a historic step for Kentucky's single largest economic development project on record. The first battery to be sold to BlueOval SK's customers came off the assembly line in Glendale Aug. 19, according to a Facebook post and email newsletter shared by the company. The batteries will be used to power Ford's F-150 Lightning pickup truck and current E-Transit, according to BlueOval SK's newsletter announcement. "We are proud to build batteries at our Kentucky 1 facility that will power next-generation electric vehicles," BlueOval SK CEO Michael Adams said in the newsletter. "The start of production is a significant milestone that strengthens our position in the electric vehicle battery market." Earlier in August, Ford delayed new generations for both models until 2028, extending a previously announced delay. A Ford spokesperson did not respond to The Courier Journal's request for comment. BlueOval SK is a joint venture between Ford and South Korean company SK On. Its $5.8 billion Kentucky site includes two plants, Kentucky 1 and Kentucky 2. Only Kentucky 1 is in production; production at Kentucky 2 was previously delayed indefinitely, due to less-than-anticipated demand for electric vehicles. "Today, Kentucky marks a historic milestone four years in the making," Gov. Andy Beshear said in a press release. "This remains the single largest investment in the history of our state, and it sparked a surge of new investment and job announcements that placed Kentucky at the center of EV-related innovation." Production is beginning just one week ahead of a major crossroads for workers. Plant staff will vote on whether or not to unionize with the United Auto Workers on Aug. 26 and 27. The workers' campaign to unionize has been driven in part by occupational safety and health concerns. Plant employees have filed a slew of complaints to state investigators, describing chemical exposure risks, inadequate personal protective equipment, respiratory hazards and more. Earlier this year, workers outright refused to work with a hazardous chemical in the plant, according to records reviewed by The Courier Journal. Recent Trump administration reversals in federal policy support for electric vehicles are also expected to pinch the market. Tax credits for EV purchases will expire at the end of September, a change that's expected to hurt consumer demand after a surge in EV adoption in recent years. Still, Ford and other automakers have indicated they plan to forge ahead on EV technology, seeing it as the inevitable direction of the industry as Chinese companies make gains. Ford recently announced a $5 billion investment in EVs, including retooling the Louisville Assembly Plant for production of a new electric midsize pickup. The batteries produced in Hardin County also stand to cut into transportation emissions, the largest contributor of U.S. greenhouse gases. If both Kentucky plants and BlueOval SK's additional plant in Tennessee produce batteries at the company's planned capacity, it would displace "over 455 million gallons of gasoline per year for the lifetime of the vehicles," according to the Department of Energy. "BlueOval SK is creating good-paying, American jobs in the heart of the Commonwealth," Adams said. "We are strengthening the domestic supply chain and driving the transition to zero-emissions transportation." Occupational safety investigations persist In previous interviews, workers have shared concerns that safety issues encountered in the past year could be amplified once the plant ramps up production. BlueOval SK has received at least one citation from state labor investigations so far, records show, related to improper fire extinguisher placement. Other incidents, including one in which a worker was sprayed with a hazardous chemical, did not result in citations. A new state investigation from July is still open, as officials look into several reports from workers this summer. One complainant described an electrocution from a faulty power adapter, causing the worker's arm to remain "in a stun state for most of the day." Another described improper lockout-tagout procedures, meant to keep potentially dangerous equipment disconnected while not in use: "...People are inside of those areas cleaning or working while the line is running and operating," according to the complaint. These recent complaints follow a series of other worker concerns raised in the last year, largely related to chemical exposure risks and access to adequate personal protective equipment, or PPE. More: EXCLUSIVE: Workers at Ford, SK On battery plant in Kentucky file for union election BlueOval SK has consistently rejected claims of safety issues, and said the plant follows all regulations. Workers have cited safety issues as a key reason for unionization efforts. Previously, the UAW has successfully unionized other EV battery plants, including projects that were associated with other Michigan-based automakers General Motors and Stellantis. Ford factories are unionized with the UAW across the U.S. and have been for decades. A UAW victory at BlueOval SK in Kentucky would give the union a greater stake in the South's growing "battery belt," where right-to-work laws leave joining a union to individual choice. BlueOval SK under pressure to hire The BlueOval SK Battery Park's 2025 start to production is consistent with the company's previously shared plans for the site, but the future of Kentucky 2, the other half of the site, is still uncertain. BlueOval SK may be under heightened pressure to ramp up operations in Kentucky 2 in the coming years, as the company strives to hit hiring goals established by the terms of its forgivable loan from the state. As part of the state incentive package BlueOval SK Battery Park received, the company must meet specific job and wage requirements. The first job and wage measurements will be taken in December 2026, according to a company presentation to lawmakers in June. By 2027, BlueOval SK Battery Park will need to employ 2,500 workers in Kentucky. The company said it expected to have roughly 1,400 workers at the Kentucky plant by May, according to filings with the National Labor Relations Board, and predicted employment of 1,800 by October and 2,500 at a later date. The NLRB, in its decision on workers' petition to unionize, called these hiring plans "speculative." "The record does not contain any evidence to establish when it expects to be fully staffed, or where the additional employees will be employed," whether in the Kentucky 1 plant or neighboring Kentucky 2, the NLRB found. This story has been updated to include a quote from Gov. Andy Beshear. Connor Giffin is an environmental reporter at The Courier Journal. Reach him directly at cgiffin@ or on X @byconnorgiffin. Contact business reporter Olivia Evans at oevans@ or on X at @oliviamevans_. This article originally appeared on Louisville Courier Journal: BlueOval SK begins production in Kentucky one week before union vote Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
2 days ago
- CBS News
Kentucky bans sale of "designer Xanax" targeted by multiple states after overdose deaths
Kentucky Gov. Andy Beshear took emergency action Monday to ban the sale of "designer Xanax," responding to a request from his state's attorney general who is leading a broader effort to combat the highly potent synthetic drug linked to dozens of overdose deaths last year in the Bluegrass State. Beshear's action in his state comes as a coalition of 21 attorneys general, led by Kentucky Attorney General Russell Coleman, is urging the U.S. Drug Enforcement Administration to take emergency action banning the unregulated drug. It poses a growing public health threat and is increasingly contributing to overdose deaths, the attorneys general said in a letter dated Monday to DEA Administrator Terry Cole. Bromazolam — widely known as "designer Xanax" — is being passed off as prescription pills including benzodiazepines, which are commonly used to treat conditions such as anxiety disorders, insomnia, and seizures, Coleman has warned. The drug has never been approved for medical use in the U.S. or elsewhere, according to a 2023 fact sheet from the Legislative Analysis and Public Policy Association. "There is zero margin of error when it comes to illicit drugs and counterfeit pills," the attorneys general said in their letter to Cole. "As parents and public officials, we must do everything possible to cut off the supply of these deadly substances through vigorous enforcement, while also continuing to promote the prevention, treatment, and recovery efforts that are saving lives across our states." In Kentucky, the classification of bromazolam as a Schedule 1 controlled substance took immediate effect following Beshear's emergency regulation. The action empowers law enforcement to make arrests for selling or possessing the drug, Beshear's office said. "This deadly drug has no place in our communities, and now we have the tools needed to get it off the streets and protect more lives," the Democratic governor said in a release. Beshear, a former Kentucky attorney general now in his second term as governor, is widely seen as a potential candidate for president in 2028. The drug he and Coleman targeted has been tied to a growing number of fatal overdoses in Kentucky and across the nation, Beshear's office said. It was detected in nearly 50 overdose deaths in Kentucky last year, the office said, even as overdose deaths in Kentucky have decreased for three years in a row. "We live in a moment when as little as one pill can kill — and is killing — our kids," Coleman said in response to Beshear's action. "I'm glad we could work together to tackle this grave threat." In their letter to the head of DEA, the attorneys general said bromazolam is being sold illicitly on the streets and online. It is highly potent and unpredictable, they said, especially when combined with opioids or other central nervous system depressants. Unlike regulated medications, illicitly manufactured bromazolam lacks quality controls, making it particularly lethal for unsuspecting users, they said. "Despite its clear dangers, bromazolam remains unscheduled at the federal level, creating significant challenges for law enforcement and public health officials trying to respond to this emerging crisis," the letter said. "Without scheduling, this drug continues to evade traditional regulatory and prosecutorial tools, hindering interdiction efforts and enabling continued distribution through illicit channels." Emergency action by the DEA would help law enforcement remove the drug from circulation, give prosecutors the ability to hold traffickers accountable and would "send a clear signal that this dangerous substance has no place on our streets," the letter said. Besides Coleman, the request to the DEA included attorneys general from Alabama, Arkansas, Florida, Georgia, Indiana, Iowa, Louisiana, Mississippi, Montana, Nebraska, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Virginia and West Virginia, Coleman's office said.
